CY1112049T1 - Χρηση ανθρακικου λανθανιου για την προληψη της νεφρικης λιθιασικης νοσου - Google Patents

Χρηση ανθρακικου λανθανιου για την προληψη της νεφρικης λιθιασικης νοσου

Info

Publication number
CY1112049T1
CY1112049T1 CY20111100432T CY111100432T CY1112049T1 CY 1112049 T1 CY1112049 T1 CY 1112049T1 CY 20111100432 T CY20111100432 T CY 20111100432T CY 111100432 T CY111100432 T CY 111100432T CY 1112049 T1 CY1112049 T1 CY 1112049T1
Authority
CY
Cyprus
Prior art keywords
prevention
kidney disease
carbon stone
renal kidney
renal
Prior art date
Application number
CY20111100432T
Other languages
English (en)
Inventor
Michael J Abrams
Gary J Bridger
Simon P Fricker
Stefan R Idzan
Original Assignee
Shire International Licensing B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire International Licensing B.V. filed Critical Shire International Licensing B.V.
Publication of CY1112049T1 publication Critical patent/CY1112049T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • External Artificial Organs (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)

Abstract

Οι παθήσεις όπως οι λίθοι των νεφρών, που χαρακτηρίζονται από ανεπιθύμητη απορρόφηση οξαλικού από την εντερική οδό υποβάλλονται πλεονεκτικά σε αγωγή δια της χρήσεως μη τοξικών αλάτων ιόντων μετάλλων σπάνιων γαιών.
CY20111100432T 2001-04-23 2011-05-04 Χρηση ανθρακικου λανθανιου για την προληψη της νεφρικης λιθιασικης νοσου CY1112049T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28590101P 2001-04-23 2001-04-23
EP02764336A EP1389102B1 (en) 2001-04-23 2002-04-22 Use of lanthanum carbonate for the prevention of kidney stone disease

Publications (1)

Publication Number Publication Date
CY1112049T1 true CY1112049T1 (el) 2015-11-04

Family

ID=23096166

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100432T CY1112049T1 (el) 2001-04-23 2011-05-04 Χρηση ανθρακικου λανθανιου για την προληψη της νεφρικης λιθιασικης νοσου

Country Status (26)

Country Link
US (2) US7192609B2 (el)
EP (1) EP1389102B1 (el)
JP (2) JP4515030B2 (el)
KR (1) KR100956013B1 (el)
CN (1) CN100438866C (el)
AT (1) ATE499943T1 (el)
AU (2) AU2002307543B2 (el)
BR (1) BR0209072A (el)
CA (1) CA2442414C (el)
CY (1) CY1112049T1 (el)
CZ (2) CZ17802U1 (el)
DE (2) DE20221760U1 (el)
DK (2) DK1389102T3 (el)
ES (1) ES2362271T3 (el)
FI (1) FIU20060390U0 (el)
HK (1) HK1064030A1 (el)
HU (1) HUP0303938A3 (el)
MX (1) MXPA03009668A (el)
NO (1) NO20034704L (el)
NZ (1) NZ528818A (el)
PL (1) PL370642A1 (el)
PT (1) PT1389102E (el)
RU (1) RU2296584C2 (el)
SI (1) SI1389102T1 (el)
WO (1) WO2002085348A1 (el)
ZA (1) ZA200308112B (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7465465B2 (en) * 2003-08-26 2008-12-16 Shire Biochem Inc. Pharmaceutical formulation comprising lanthanum compounds
US7381428B2 (en) * 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
CA2574450C (en) * 2004-07-27 2011-07-19 Shire Pharmaceuticals, Inc. Method of treating hyperphosphataemia using lanthanum hydroxycarbonate
US20070104799A1 (en) * 2005-11-09 2007-05-10 Shire International Licensing B.V. Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
WO2009118760A2 (en) * 2008-03-26 2009-10-01 Matrix Laboratories Limited Lanthanum composition
TWI446916B (zh) 2010-05-12 2014-08-01 Spectrum Pharmaceuticals Inc 鹼式碳酸鑭、碳酸氧鑭及其製備方法及用途
RU2657755C1 (ru) * 2017-07-10 2018-06-15 Александр Александрович Кролевец Способ получения нанокапсул солей лантаноидов в каррагинане
AU2021218729A1 (en) * 2020-02-13 2022-09-08 Lawrence Livermore National Security, Llc Methods of sequestering target elements
WO2024003337A1 (en) * 2022-07-01 2024-01-04 Amgmt Orally administrable pharmaceutical dosage form comprising lanthanum and its use in a method of treatment of hyperoxaluria

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1668562C3 (de) * 1967-12-08 1975-01-30 Pharmazeutische Fabrik Evers & Co, 2080 Pinneberg Cergluconat, Verfahren zu seiner Herstellung und dieses enthaltende pharmazeutische Präparate
DE3046580A1 (de) * 1980-12-11 1982-07-01 Leskovar, Peter, Dr.-Ing., 8000 München Harnsteinaufloesende mittel
DE3213139A1 (de) * 1980-12-11 1983-10-20 Leskovar, Peter, Dr.-Ing., 8000 München Harnsteinaufloesende mittel
JPS614528A (ja) 1984-06-15 1986-01-10 Arubatsuku Service Kk 水溶性ガスの高純度溶液の製造装置
JPS614529A (ja) * 1984-06-15 1986-01-10 Asahi Chem Ind Co Ltd リン酸イオンの吸着剤
JPH06705B2 (ja) 1985-12-19 1994-01-05 旭化成工業株式会社 リン酸イオンの固定化剤
US5171583A (en) * 1988-10-21 1992-12-15 The Regents Of The University Of California Treatment of osteoporosis using potassium bicarbonate
US5342604A (en) * 1988-10-31 1994-08-30 The Dow Chemical Company Complexes possessing ortho ligating functionality
US5696239A (en) * 1988-10-31 1997-12-09 The Dow Chemical Company Conjugates possessing ortho ligating functionality and complexes thereof
CA2117351C (en) * 1992-01-13 1998-03-03 Julian Belknap Lo Preparation of tablets of increased strength
RU2061040C1 (ru) 1994-05-23 1996-05-27 Акционерное общество "Русский йогурт" Штамм бактерий lactobacillus plantarum, обладающий способностью снижать уровень оксалата и используемый для получения препаратов и продуктов питания для профилактики и лечения гипероксалурии
US5562921A (en) * 1994-07-15 1996-10-08 Sherman; Bernard C. Stable solid pharmaceutical compositions containing enalapril maleate
GB9506126D0 (en) 1995-03-25 1995-05-10 Johnson Matthey Plc Pharmaceutical composition and method
US5951958A (en) * 1996-07-10 1999-09-14 Shin-Etsu Chemical Co., Ltd. Method for the preparation of rare earth phosphate of low overstoichiometric phosphorous content
US5902825A (en) * 1997-01-07 1999-05-11 Mitreoak, Ltd. Composition and method for the palliation of pain associated with diseases of the bone and bone joints
ES2334409T3 (es) 1997-05-23 2010-03-09 Oxthera, Inc., Microorganismos degradantes del oxalato o enzimas degradantes del oxalato para prevenir enfermedades relacionadas con el oxalato.
US6355242B1 (en) 1997-05-23 2002-03-12 Ixion Biotechnology, Inc. Materials and methods for treating or preventing oxalate-related disease
US5985938A (en) 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
US6160016A (en) * 1999-12-22 2000-12-12 Wisconsin Alumni Research Foundation Phosphorus binder
US20040082588A1 (en) * 2002-09-30 2004-04-29 Schering Corporation Methods for treating disorders of calcium homeostasis
US7465465B2 (en) * 2003-08-26 2008-12-16 Shire Biochem Inc. Pharmaceutical formulation comprising lanthanum compounds

Also Published As

Publication number Publication date
ES2362271T3 (es) 2011-06-30
CZ298280B6 (cs) 2007-08-15
ZA200308112B (en) 2005-01-17
EP1389102A4 (en) 2004-07-14
MXPA03009668A (es) 2004-02-12
CZ20032880A3 (cs) 2004-01-14
CA2442414C (en) 2011-02-01
PL370642A1 (en) 2005-05-30
AU2002307543B2 (en) 2006-04-27
EP1389102A1 (en) 2004-02-18
HK1064030A1 (en) 2005-01-21
DK200600251U4 (da) 2007-12-28
JP2005507369A (ja) 2005-03-17
RU2003133991A (ru) 2005-04-20
CZ17802U1 (cs) 2007-09-03
US20020155168A1 (en) 2002-10-24
AU2006203055A1 (en) 2006-08-10
CN1503668A (zh) 2004-06-09
SI1389102T1 (sl) 2011-07-29
US7192609B2 (en) 2007-03-20
FIU20060390U0 (fi) 2006-09-22
CA2442414A1 (en) 2002-10-31
EP1389102B1 (en) 2011-03-02
US20070116782A1 (en) 2007-05-24
AU2006203055B2 (en) 2008-12-18
PT1389102E (pt) 2011-06-07
ATE499943T1 (de) 2011-03-15
DE60239329D1 (de) 2011-04-14
CN100438866C (zh) 2008-12-03
WO2002085348A1 (en) 2002-10-31
JP2009173684A (ja) 2009-08-06
DK200600251U1 (da) 2007-01-12
NZ528818A (en) 2008-09-26
HUP0303938A2 (hu) 2004-04-28
DE20221760U1 (de) 2007-08-16
KR20040018362A (ko) 2004-03-03
DK1389102T3 (da) 2011-06-06
NO20034704L (no) 2003-11-25
KR100956013B1 (ko) 2010-05-06
RU2296584C2 (ru) 2007-04-10
HUP0303938A3 (en) 2012-09-28
JP4515030B2 (ja) 2010-07-28
BR0209072A (pt) 2006-02-07
NO20034704D0 (no) 2003-10-21

Similar Documents

Publication Publication Date Title
CY1112049T1 (el) Χρηση ανθρακικου λανθανιου για την προληψη της νεφρικης λιθιασικης νοσου
LTPA2020503I1 (lt) Rapamicino darinys, skirtas kasos vėžio gydymui
EA200501771A1 (ru) Лиганды каннабиноидных рецепторов и их применения
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
AP2212A (en) Phosphonates, Monophosphonamidates, Bisphosphonamidates for the treatment of viral diseases.
NO20041446L (no) Fremgangsmate for sinkgjenvinning.
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
IL159563A0 (en) Method for kidney disease detection by protein profiling
WO2007061737A3 (en) FUSED BICYCLIC mTOR INHIBITORS
EA200300566A1 (ru) Применение cci-779 в качестве противоопухолевого средства
CY1107074T1 (el) Συνθεση εναντιομερων 4-αμινο-θαλιδομιδης
IS7684A (is) Ný efnasambönd, blöndur og aðferðir til að meðhöndla bólgusjúkdóma og -ástand
CY1108041T1 (el) Αναστολεις της rho-κινασης
EA200700225A1 (ru) Аналоги тетрапептида
UA88638C2 (ru) Бета-карболины, полезные для лечения воспалительного заболевания
DE602004012562D1 (de) Strahlaufbereitungssystem
EA200601217A1 (ru) Новые конденсированные пирролокарбазолы
ATE434619T1 (de) Thienodibenzazulenverbindungen als tumornekrosefaktorhemmer
DK1325011T3 (da) Fremgangsmåder og forbindelser til behandling af proliferative sygdomme
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
CY1106026T1 (el) Αρυλσουλφοναμιδια ως ανταγωνιστες της σepοτονινης για την αγωγη της παχυσαρκιας
MA29266B1 (fr) Traitement de tumeurs metastatiques
WO2003084475A3 (en) INHIBITORS OF THE S100-p53 PROTEIN-PROTEIN INTERACTION AND METHOD OF INHIBITING CANCER EMPLOYING THE SAME
FI20060576A (fi) Menetelmiä fenolin puhdistamiseksi
MXPA03008946A (es) Metodos para sintetizar compuestos que contienen fenol.